Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/news-on-infantile-haemangioma-part-1-clinical-course-and-vFTrDCcoyf
References (31)
-
(2014)
Biology of Infantile Hemangioma -
B. Narváez‐Moreno, M. Sendín-Martín, Guillermo Jiménez-Thomas, Rocío Sánchez-Silva, Nela Syárez-Luna, M. Echevarría, J. Bernabéu-Wittel (2019)
Expression patterns of aquaporin 1 in vascular tumoursEuropean Journal of Dermatology, 29
-
Angela Queisser, L. Boon, M. Vikkula (2018)
Etiology and Genetics of Congenital Vascular Lesions.Otolaryngologic clinics of North America, 51 1
-
P. Mabeta (2018)
Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic TargetingInternational Journal of Molecular Sciences, 19
-
E. Boye, M. Jinnin, B. Olsen (2009)
Infantile Hemangioma: Challenges, New Insights, and Therapeutic PromiseJournal of Craniofacial Surgery, 20
-
Eeva Castrén, P. Salminen, M. Vikkula, A. Pitkäranta, T. Klockars (2016)
Inheritance Patterns of Infantile HemangiomaPediatrics, 138
-
M. Luu, I. Frieden (2013)
Haemangioma: clinical course, complications and managementBritish Journal of Dermatology, 169
-
Ying Wang, Jiarui Chen, Weiqing Tang, Yanping Zhang, Xiaoyan Li (2017)
Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 85
-
Jeffrey Walter, Francine Blei, Jennifer Anderson, Seth Orlow, M. Speer, Douglas Marchuk (1999)
Genetic mapping of a novel familial form of infantile hemangioma.American journal of medical genetics, 82 1
-
Xueqing Li, Yuanzheng Chen, Cong Fu, Hongwen Li, Kun Yang, Jianhai Bi, R. Huo (2020)
Characterization of epigenetic and transcriptional landscape in infantile hemangiomas with ATAC-seq and RNA-seq.Epigenomics
-
Anita Haggstrom, B. Drolet, E. Baselga, S. Chamlin, M. Garzon, K. Horii, A. Lucky, A. Mancini, D. Metry, B. Newell, A. Nopper, I. Frieden (2006)
Prospective Study of Infantile Hemangiomas: Clinical Characteristics Predicting Complications and TreatmentPediatrics, 118
-
D. Metry, G. Heyer, C. Hess, M. Garzon, Anita Haggstrom, P. Frommelt, D. Adams, D. Siegel, K. Hall, J. Powell, I. Frieden, B. Drolet (2009)
Consensus Statement on Diagnostic Criteria for PHACE SyndromePediatrics, 124
-
J. Byun, H. An, S. Yeom, Seok-Jong Lee, H. Chung (2018)
NDRG1 and FOXO1 regulate endothelial cell proliferation in infantile haemangiomaExperimental Dermatology, 27
-
Yi Ji, Siyuan Chen, Kai Li, Xian-min Xiao, S. Zheng, Ting Xu (2013)
The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cellsCell Division, 8
-
M. Kleinman, M. Greives, Samara Churgin, K. Blechman, Eric Chang, Daniel Ceradini, O. Tepper, G. Gurtner (2007)
Hypoxia-Induced Mediators of Stem/Progenitor Cell Trafficking Are Increased in Children With HemangiomaArteriosclerosis, Thrombosis, and Vascular Biology, 27
-
J. Saerens, H. Leye, S. Janmohamed (2021)
News on infantile haemangioma. Part 2: therapy and evaluationClinical and Experimental Dermatology, 46
-
Christine Léauté-Labrèze, John Harper, P. Hoeger (2017)
Infantile haemangiomaThe Lancet, 390
-
A. Vredenborg, S. Janmohamed, Peter Laat, G. Madern, A. Oranje (2013)
Multiple cutaneous infantile haemangiomas and the risk of internal haemangiomaBritish Journal of Dermatology, 169
-
V. Colonna, Leonardo Resta, Anna Napoli, E. Bonifazi (2010)
Placental hypoxia and neonatal haemangioma: clinical and histological observationsBritish Journal of Dermatology, 162
-
P. North, M. Waner, A. Mizeracki, R. Mrak, R. Nicholas, J. Kincannon, J. Suen, M. Mihm (2001)
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta.Archives of dermatology, 137 5
-
L. Boon, F. Ballieux, M. Vikkula (2011)
Pathogenesis of vascular anomalies.Clinics in plastic surgery, 38 1
-
Shengqiang Wang, L. Ren, Guanguo Shen, Mingming Liu, Jun Luo (2020)
The knockdown of MALAT1 inhibits the proliferation, invasion and migration of hemangioma endothelial cells by regulating MiR-206 / VEGFA axis.Molecular and cellular probes
-
Yuan Ding, Jingzhan Zhang, Shirong Yu, Fang Xiang, Xiao-Jing Kang (2019)
Risk factors for infantile hemangioma: a meta-analysisWorld Journal of Pediatrics, 16
-
Yanlin Wang, Miaomiao Li, Changxian Dong, Yu-chun Ma, Li Xiao, Song Zuo, Yubin Gong, Tengfei Ren, Bin Sun (2019)
Linc00152 knockdown inactivates the Akt/mTOR and Notch1 pathways to exert its anti‐hemangioma effectLife Sciences, 223
-
S. Jong, T. Itinteang, Aaron Withers, P. Davis, S. Tan (2016)
Does hypoxia play a role in infantile hemangioma?Archives of Dermatological Research, 308
-
R. Hyland, K. Komlosi, Brandon Alleman, M. Tolnai, Laura Wood, E. Bell, T. Ertl (2013)
Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesisEuropean Journal of Pediatrics, 172
-
S. Janmohamed, S. Janmohamed, T. Brinkhuizen, J. Hollander, G. Madern, Peter Laat, M.A.M. Steensel, Arnold Oranje (2015)
Support for the hypoxia theory in the pathogenesis of infantile haemangiomaClinical and Experimental Dermatology, 40
-
Jun-bo Tu, Quan-Yan Li, Fei Jiang, Xiao-yi Hu, Rui-Zhao Ma, Q. Dong, Hao Zhang, P. Pattar, Shixin Li (2014)
Pingyangmycin stimulates apoptosis in human hemangioma-derived endothelial cells through activation of the p53 pathway.Molecular medicine reports, 10 1
-
M. Wassef, F. Blei, D. Adams, A. Alomari, E. Baselga, A. Berenstein, P. Burrows, I. Frieden, M. Garzon, J. López-Gutiérrez, D. Lord, Sally Mitchel, J. Powell, J. Prendiville, M. Vikkula (2015)
Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular AnomaliesPediatrics, 136
-
E. Baselga, E. Roé, Julien Coulie, Fania Muñoz, L. Boon, C. McCuaig, Á. Hernández-Martín, I. Gich, L. Puig (2016)
Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.JAMA dermatology, 152 11
-
Stephen Huang, H. Tu, J. Harney, M. Venihaki, A. Butte, H. Kozakewich, S. Fishman, P. Larsen (2000)
Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas.The New England journal of medicine, 343 3
- Copyright
- © 2021 British Association of Dermatologists
- ISSN
- 0307-6938
- eISSN
- 1365-2230
- DOI
- 10.1111/ced.14502
- Publisher site
- See Article on Publisher Site
Abstract
SummaryCurrently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta‐blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta‐blockers. In Part 1 of this review we will discuss the state‐of‐the‐art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.
Journal
Clinical and Experimental Dermatology – Oxford University Press
Published: Apr 1, 2021